Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Regulatory News (AVCT)

Share Price Information for Avacta Group (AVCT)

Share Price is delayed by 15 minutes
Get Live Data
72.00    2.00 (2.86%)
Bid:
71.00
Ask:
73.00
Spread: 2.00 (2.817%)
Market Cap: £327.68m
AVCT Live PriceLast checked at - London Stock Exchange

Intraday Avacta Group Share Chart

Re Agreement

3 Sep 2007 07:00

Avacta Group plc

Development Contract with the MOD's Defence science and technology laboratory

Field Detection of Liquid Chemicals

Avacta Group plc ("Avacta"), which develops detection and analysis technology aimed at the defence & security, pharmaceutical and clinical diagnostics markets, announces a contract with the Defence science and technology laboratory (Dstl), which is part of the UK Ministry of Defence.

Avacta is developing methods of analysing liquids using laser spectroscopy. The goal is to enable the rapid detection of liquids in the field.

Professor Alastair Smith, Chief Executive, Avacta, commented:

"We are delighted with the new contract for the development of a robust, prototype device. Laser detection and diagnostic devices are a key part of Avacta's portfolio of technologies and this contract with the MOD is an important step for the company."

3 September 2007Enquiries:Avacta Group plc Tel: 0870 835 4367 Alastair Smith, Chief Executive Nexus Financial Ltd Tel: 020 7451 7050 Nicholas Nelson/Kathy Boate nicholas.nelson@nexusgroup.co.uk W.H. Ireland Ltd Tel: 0161 832 2174 David Youngman/Robin Gwyn BankOra Ltd Tel: 020 7099 1942 Michael Brennan/Henry Turcan Notes to Editors:About Avacta

Avacta was spun-out from the University of Leeds in 2004 by its current management team as a biophysics company, with the aim of combining the disciplines of physics and biology to develop innovative technologies and expert technical services to address needs in the pharmaceutical, defence and clinical diagnostics markets. Avacta has a core bio-analytical technology development programme addressing the needs of the biopharmaceutical sector to fully characterise their new products at the earliest stage in their development to reduce the risk of late stage failure. High value solutions in defence and clinical diagnostics are also being provided by Avacta's development programmes. A successful and growing part of the Avacta business model is its technical services arm, Avacta Analytical Ltd which is focused on providing leading edge contract research to the biopharmaceutical and healthcare/personal-care materials sectors. Avacta listed on AIM in August 2006 through the reverse takeover of Readybuy plc which changed its name to Avacta Group plc.

AVACTA GROUP PLC
Date   Source Headline
22nd Apr 20202:30 pmRNSHolding(s) in Company
22nd Apr 20209:05 amRNSSecond Price Monitoring Extn
22nd Apr 20209:00 amRNSPrice Monitoring Extension
22nd Apr 20207:00 amRNSAvacta/Cytiva Partnership Ahead of Schedule
20th Apr 20209:05 amRNSSecond Price Monitoring Extn
20th Apr 20209:00 amRNSPrice Monitoring Extension
17th Apr 20207:00 amRNSNotice of Results - Update
16th Apr 20204:41 pmRNSSecond Price Monitoring Extn
16th Apr 20204:36 pmRNSPrice Monitoring Extension
16th Apr 20202:05 pmRNSSecond Price Monitoring Extn
16th Apr 20202:00 pmRNSPrice Monitoring Extension
15th Apr 20209:05 amRNSSecond Price Monitoring Extn
15th Apr 20209:00 amRNSPrice Monitoring Extension
14th Apr 20205:30 pmRNSHolding(s) in Company
14th Apr 20202:06 pmRNSSecond Price Monitoring Extn
14th Apr 20202:00 pmRNSPrice Monitoring Extension
14th Apr 202011:05 amRNSSecond Price Monitoring Extn
14th Apr 202011:00 amRNSPrice Monitoring Extension
9th Apr 20204:41 pmRNSSecond Price Monitoring Extn
9th Apr 20204:37 pmRNSPrice Monitoring Extension
8th Apr 20202:05 pmRNSSecond Price Monitoring Extn
8th Apr 20202:00 pmRNSPrice Monitoring Extension
8th Apr 202011:05 amRNSSecond Price Monitoring Extn
8th Apr 202011:00 amRNSPrice Monitoring Extension
8th Apr 20209:05 amRNSSecond Price Monitoring Extn
8th Apr 20209:00 amRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSAvacta & Cytiva Collaborate on COVID-19 Rapid Test
6th Apr 20205:45 pmRNSHolding(s) in Company
6th Apr 20202:06 pmRNSSecond Price Monitoring Extn
6th Apr 20202:01 pmRNSPrice Monitoring Extension
6th Apr 20207:00 amRNSProposed Placing to raise £3.75 million
2nd Apr 20207:01 amRNSAppointment of Joint Broker
2nd Apr 20207:00 amRNSSubscription to raise £2 million
26th Mar 202011:05 amRNSSecond Price Monitoring Extn
26th Mar 202011:00 amRNSPrice Monitoring Extension
24th Mar 20202:06 pmRNSSecond Price Monitoring Extn
24th Mar 20202:00 pmRNSPrice Monitoring Extension
16th Mar 20204:42 pmRNSSecond Price Monitoring Extn
16th Mar 20204:38 pmRNSPrice Monitoring Extension
10th Mar 20207:00 amRNSShareholder/Investor Meeting and Presentation
13th Feb 20207:00 amRNSNotice of Results
11th Feb 20207:00 amRNSShare Incentive Plan/Issue of Equity
3rd Feb 20207:00 amRNSAvacta and Daewoong Agreement
29th Jan 20202:45 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSSuccessful initial proof-of-concept
23rd Jan 20207:00 amRNSTrading Update
21st Jan 20207:00 amRNSDirector Appointment
8th Jan 20207:00 amRNSAvacta and Daewoong Establish Joint Venture
26th Nov 20199:00 amRNSHolding(s) in Company
22nd Nov 20198:41 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.